Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330992 | 0.84 | XIAP (0.56) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL330837 | 0.83 | XIAP (0.43) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL332059 | 0.81 | TMPRSS4 (0.49) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL330487 | 0.80 | MEN1 (0.46) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL330671 | 0.80 | PLTP (0.41) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL330259 | 0.79 | KMT2A (0.60) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL330674 | 0.77 | RAB9A (0.64) | KMT2AMEN1NPC1RAB9ARXFP1 | |
| SCHEMBL3278037 | 0.77 | ADORA3 (0.52) | XIAPKMT2AMEN1NPC1RAB9A | |
| SCHEMBL331142 | 0.75 | MAPT (0.48) | KMT2AMEN1NPC1RAB9ARXFP1 | |
| SCHEMBL330302 | 0.74 | ADORA3 (0.67) | KMT2AMEN1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1658872-B | Antiallergic agent | INST MED MOLECULAR DESIGN INC | 2010-09-22 | — | — | CN | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| CN-100506221-C | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2009-07-01 | — | — | CN | disclosed |
| CN-100490793-C | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2009-05-27 | — | — | CN | disclosed |
| CN-100464742-C | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2009-03-04 | — | — | CN | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| CN-100379410-C | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2008-04-09 | — | — | CN | disclosed |
| CN-101103977-A | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-16 | — | — | CN | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1658849-A | Inhibitors of AP-1 and NFAT activation | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658858-A | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658854-A | Immune related protein kinase inhibitors | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658857-A | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658872-A | Antiallergic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658856-A | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658850-A | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | XIAP 244/4885KMT2A 3909/4885MEN1 4484/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | XIAP 1760/4885KMT2A 302/4885MEN1 2257/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | XIAP 1239/4885KMT2A 1205/4885MEN1 3560/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | XIAP 1624/4885KMT2A 283/4885MEN1 2381/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | XIAP 1517/4885KMT2A 1392/4885MEN1 4288/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | XIAP 1578/4885KMT2A 2393/4885MEN1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.